Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.

Extensive safety testing and manufacturing improvements have now made it possible to bring the drug back to the US market.

Childhood exposure linked to modestly better cognition in secondary school, but no significant difference seen at age ~60 years.

HealthDay News — Eli Lilly reached a major milestone Friday, becoming the first healthcare company in the world to hit a $1 trillion market value. The drug company briefly crossed the trillion-dollar ...

Based on the efficacy results, Novo Nordisk has made the decision to discontinue the 1-year extension periods for these trials.

New postmarketing reports link Adzynma to neutralizing antibodies and a fatality, leading the FDA to evaluate the need for updated labeling.

Benefits of metformin outweigh risks among young people with overweight or obesity and treated with second-gen antipsychotics.

Mindfulness-based interventions beneficial for nurses, midwives, while professional coaching effective for physicians ...

HealthDay News — Health officials are warning parents that recalled ByHeart baby formula is still showing up on store shelves, even as lab tests confirm it was contaminated with dangerous bacteria ...

Asundexian is designed to reduce thrombus formation without increasing bleeding risk by selectively inhibiting FXIa.

HealthDay News — A quadrivalent nucleoside-modified messenger RNA (modRNA) influenza vaccine is superior to a licensed inactivated quadrivalent influenza vaccine, according to a study published in the ...

Osvyrti is suppled as a 60mg/mL single-dose prefilled syringe for SC administration and Jubereq is supplied as 120mg/1.7mL single-dose vial for SC administration.